Treatment of mice with the carcinogen azoxymethane (AOM) induces a number of lesions in the colon, including hyperplastic lesions, as well adenomas and carcinomas in situ. Inbred strains of mice show different responses to AOM-induced carcinogenesis. A/J mice are highly susceptible and develop a greater number of hyperplastic lesions and tumors (15-70 tumors per mouse) than resistant C57BL/6J mice (0-6 tumors per mouse). Susceptibility to AOM-induced tumors segregates as a co-dominant trait in (A Â B6)F1 hybrids. Using a set of 23 AcB and BcA recombinant congenic mouse strains derived from A/J (susceptible) and B6 (resistant) parents, we observed that the number of hyperplastic lesions and tumors induced by AOM was under different genetic controls in AcB/BcA strains. The multiplicity of AOM-induced tumors is controlled by a major locus that we have mapped on the distal portion of chromosome 3, to which we have given the temporary designation colon cancer susceptibility locus 3 (Ccs3). B6 and A/J alleles at Ccs3 are associated with resistance and susceptibility, respectively. Haplotype analysis in key informative AcB/BcA strains restricts the size of the Ccs3 locus to a 14 Mb segment that contains 94 annotated genes. The expression level of all these genes in normal colon has been established by transcript profiling with microarrays, and has led to the identification of a subset of positional candidates that are expressed at high levels in this tissue. The 4q and 1p human chromosomal segments sharing syntenic homology with the mouse Ccs3 segment are known to be associated with inflammatory bowel diseases and colorectal tumors in humans, suggesting that the study of the mouse Ccs3 locus may help further the pathogenesis of these human conditions.
Introduction
Colorectal cancer (CRC) is the second most common cause of cancer in Western societies. In the United States, there are an estimated 108 000 new cases of colon and 41 000 cases of rectal cancer every year, with an estimated fatality rate of 30% (www.cancer.gov/ cancertopics/types/colon-and-rectal). CRC arises from a deregulation in the organization, proliferation, differentiation and apoptosis of colonic epithelial cells. Pathogenesis is a progressive multistage process, which includes histological landmarks associated with alterations in specific genes and biochemical pathways (Rajagopalan et al., 2003; Wood et al., 2007) . The earliest manifestation of colorectal neoplasia is the appearance of aberrant crypt foci (ACF), where a few colonic crypts may show presence of dysplastic cells. The ACF will progress to either hyperplastic or adenomatous polyps that represent benign tumors protruding into the lumen. Adenomas eventually progress to carcinomas that show major structural disorganization and invasiveness. This sequence of events in most cases is due to mutations first in the Adenomatous polyposis coli (APC) gene whereby normal glands form ACF. Additional mutations in the RAS gene underlie progression of ACF to polyps and further alterations in SMAD2, SMAD4, DCC, p53 and other oncogenes or tumor suppressor genes support progression to invasive carcinoma (Rajagopalan et al., 2003; Wood et al., 2007) .
The onset, progression and ultimate outcome of CRC is influenced by a combination of intrinsic predisposing genetic factors, and extrinsic environmental factors including diet, lifestyle, chronic inflammation and others (Demant, 2003; de la Chapelle, 2004) . A small proportion (o10%) of CRC cases show a hereditary and highly penetrant genetic component. Patients with familial adenomatous polyposis (FAP) develop thousands of adenomas in the colon and rectum from late childhood into adulthood, which if left untreated progress to aggressive carcinomas. Most FAP tumors result from germ-line mutations in the APC gene (de la Chapelle, 2004) . Another hereditary syndrome associated with CRC is hereditary nonpolyposis colon cancer (also called Lynch syndrome), which is caused by germ-line mutations in the mismatch repair genes MSH2, MLH1, MSH6 and PMS2. In these hereditary syndromes, progression to CRCs often implicates additional alterations in the APC, K-RAS, LKB1, SMAD4, AXIN2, BMPR1, CTNNB1, CCND1 and p53 (de la Chapelle, 2004) . Conversely, most cases (>90%) of CRC are sporadic with no prior family history. Predisposition in these cases is thought to involve a complex and heterogeneous genetic component with a plurality of low penetrance genetic effects further modified by environmental factors (Demant, 2003) . Indeed, recent whole-genome association studies in thousands of familial and sporadic cases of CRC from different populations have pointed to a complex genetic component with contributions from chromosomal regions 8q24, 15q13, 18q21, 10p14, 8q23.3, 11q23, 14q22.2, 16q22.1, 19q13.1 and 20p12.3 (Tomlinson et al., 2007, 2008; Zanke et al., 2007; Jaeger et al., 2008; Study, 2008; Tenesa et al., 2008) .
Although the identification of individual causative genes in such complex traits is difficult in humans, the genetic component of CRC susceptibility has been studied in mice, where CRC can be induced by chronic exposure to the carcinogen 1,2-dimethylhydrazine (DMH) or its metabolite azoxymethane (AOM) (Dragani, 2003) . These carcinogens induce different types of lesions over time, including ACF, adenomas, carcinoma in situ and adenocarcinomas (Suzui et al., 2002) . Colorectal tumors induced by these carcinogens harbor genetic lesions similar to those found in human CRCs, including mutations in Apc, K-ras and b-catenin (Takahashi and Wakabayashi, 2004) . Inbred mouse strains vary dramatically in susceptibility to carcinogeninduced CRC, as determined by the number of tumors (>1 mm diameter) arising over time: strains such as A/J, FVB/J, ICR/Ha, SWR and STS/A being susceptible and strains such as C57BL/6, BALB/c, AKR and DBA/ 2J being resistant to DMH and/or AOM-induced CRC (Evans et al., 1977; Deschner et al., 1988; Papanikolaou et al., 1998; Nambiar et al., 2003) . In F1 hybrids, susceptibility tends to be co-dominant, and segregation analyses and whole-genome scanning have pointed to loci on chromosomes 3 (CBA Â C57BL/6 cross) (Angel et al., 2000) , 4 (B10.O20 Â O20 cross) (Fijneman and Demant, 1995) and 12 (ICR/Ha Â C57BL/6Ha cross) (Jacoby et al., 1994) , as contributing in a strain-specific manner to susceptibility to DMH-induced CRC. Additional studies in congenic strains derived from BALB/cHeA and STS/A have suggested that as many as 15 loci (Scc1-Scc15, on chromosomes 1, 2, 4, 10, 11 and 18) may contribute to differential susceptibility to CRC in these two strains Van Wezel et al., 1996; Ruivenkamp et al., 2003) , highlighting the complex nature of CRC susceptibility in mice. One such locus, Scc1, was identified by positional cloning as the Ptprj tyrosine phosphatase . The human PTPRJ gene was subsequently shown to undergo loss of heterozygosity in sporadic CRC (Ruivenkamp et al., 2003) , indicating that genes causing CRC in mice may also be of clinical relevance for human CRC (Dragani, 2003) .
To investigate the genetic control of differential susceptibility of susceptible A/J (A) and resistant C57BL/6 (B) to AOM-induced colon carcinogenesis, we have taken advantage of a set of 35 reciprocal AcB/ BcA recombinant congenic strains (RCS) derived in our laboratory from A/J and B6 parents (Fortin et al., 2001) . The AcB/BcA set (13 AcB and 22BcA) was derived by systematic inbreeding from a double backcross (N3), and each strain contains a small amount (12.5%) of DNA from one parent fixed as a set of discrete congenic segments on the background (87.5%) of the other parent. The AcB/BcA set has been genotyped for 625 informative markers (average spacing 2.6 cM) and the position of all congenic fragments has been established. Individual resistance/susceptibility loci contributing to a simple or to a complex trait may have segregated in individual RCS and can be studied in isolation, both for gene-mapping and gene identification experiments, but also for elucidating the contributions of single genes to the overall phenotype. The relatively small size of the congenic segments fixed in individual RCS facilitates the search and testing of candidate genes.
We have tested 23 of the 35 AcB/BcA strains for susceptibility to AOM-induced CRC, as measured by the multiplicity of tumors scored 19 weeks following initiation of AOM exposure. The AcB/BcA strains segregated into two groups being either susceptible or resistant, suggesting a simple genetic control of susceptibility. An analysis of the genotype/phenotype correlation indicates that a major gene on the distal part of chromosome 3 is responsible for the effect.
Results

AOM-induced colorectal tumors in A/J mice
The AOM treatment used in our study (eight weekly injections, 10 mg/kg intraperitoneally) induced a number of microscopic and macroscopic lesions (Figure 1 ), which were defined according to clinical standards. When colons were examined 19 weeks following initiation of treatment, two types of macroscopic lesions were detected ( Figures 1A and B) . These lesions were restricted to the distal portion of the colon and were rarely seen in the proximal portion. In addition, we did not observe metastatic lesions to secondary sites. Flat lesions with clearly defined circular boundaries were identified ( Figure 1B ), and these were scored as hyperplastic lesions in a first quantitative measure of susceptibility (see below). Tumors (>1 mm diameter) protruding into the lumen of the colon, and showing different degrees of vascularization, were also detected ( Figure 1A ). The multiplicity of these tumors was also used as a second quantitative trait in our genetic analyses.
Microscopic examination of hyperplastic lesions revealed the presence of ACF characterized by the absence of mucin and large nuclei in the epithelial cells ( Figure 1C,b) . These lesions exhibited low-grade dys-plasia with nontubular morphologies that are lined by epithelium with depletion of mucin and large, irregular nuclei ( Figure 1C,c) , or high-grade dysplasia with neoplastic cells with depleted mucin and pleomorphic nuclei ( Figure 1C,d ). On the other hand, the large tumors consisted mainly of adenomas and intramucosal carcinomas. Adenomas were defined as proliferation of the colonic epithelium with low-or high-grade dysplasia (degree of cytological atypia and architectural complexity). The designation of intramucosal carcinomas was used when there was dense crowding evidence of high-grade dysplastic epithelial cells packed in the lamina propria, and characterized by prominent backto-back glands and a cribriform architecture, but without invasion into the submucosa. Overall, the tumors we observed rarely breached the muscularis mucosa.
Differential response of C57BL/6J and A/J mice to AOM chemical carcinogenesis Differential response of A/J (susceptible, S) and C57BL/ 6J (resistant, R) to AOM (Papanikolaou et al., 1998; Nambiar et al., 2003) or DMH-induced (Evans et al., 1977) colon cancer has been known for many years. However, the nature of the genetic control, about the number and identity of the genes responsible, has remained unknown. A number of experiments were conducted to optimize the efficacy of the AOM carcinogenesis protocol, and to establish conditions to unambiguously discriminate between susceptible and resistant mice, while minimizing discomfort to the experimental animals.
In a first experiment, A/J and B6 mice were injected i.p. with AOM (10 mg/kg) once per week for 8 consecutive weeks, and groups of animals (n ¼ 5) were killed at weeks 10, 14 and 20. Colons were washed with phosphate-buffered saline (PBS), dissected and examined for the presence of either hyperplastic lesions and/ or tumors that were scored (Figure 2a) . AOM caused the appearance of hyperplastic lesions in both A/J and B6 colons, but their numbers were greater (by twofold) in A/J at 14 and 20 weeks (14 weeks, average of 3.2 for B6 vs 7.8 for A/J; Po0.05). AOM-treated A/J mice developed tumors starting at 10 weeks (average 1.2 per mouse), and their numbers progressively increased at 14 weeks (average 6.6 per mouse; Po0.05) and up to 20 weeks (average 21.8 per mouse; Po0.01). At that time point, the distal colons of A/J were dotted with 20-30 clearly identifiable tumors, an example of which is shown in Figure 3 . Over the same 20 weeks observation period, B6 mice did not develop tumors, and only a single tumor was detected in a B6 mouse at week 20 in this experiment. These results indicate that under these treatment conditions, A/J mice are susceptible to AOMinduced colon tumors whereas B6 mice are resistant. (Figure 2b ) to determine the mode of inheritance of the susceptibility trait. On average, the number of hyperplastic lesions found in A/J mice (average 7.0 per mouse) was greater than in B6 (average 3.6 per mouse; Po0.01), whereas F1 hybrids showed numbers that were statistically similar to A/J and distinct from B6 (average 6.6 per mouse; Po0.01) (Figure 2b , left panel), suggesting that susceptibility to AOM-induced hyperplastic lesions is inherited as a dominant trait in (A Â B6)F1. A similar analysis of tumor multiplicity at week 19 revealed very few tumors in B6 (average 2.4 per mouse), high prevalence in A/J (average 41 per mouse; Po0.01) and somewhat intermediate tumor multiplicity in (A/J Â B6)F1 (average 21 per mouse), which was statistically different from numbers recorded in either parents (Po0.01). This suggests that susceptibility to AOM-induced colon tumors is inherited in a codominant manner in (A/J Â B6)F1 hybrids.
Response of AcB/BcA recombinant congenic strains to AOM-induced colon carcinogenesis To study the genetic control of differential susceptibility of A/J and B6 mice to AOM-induced colon carcinogenesis, we phenotyped 23 of the 35 available AcB/BcA RCS. By virtue of the breeding scheme used in their derivation, the AcB/BcA strain set constitutes a powerful tool to characterize the genetic control of a A/J vs B6 interstrain difference in a given phenotype, allowing (1) efficient and accurate mapping of a major monogenic effect (Fortin et al., 2001) , and (2) Between 5 and 15 animals of each strain were treated with AOM, and their colon were scored for the presence of hyperplastic lesions and tumors. All strains were tested at least twice. Representative examples of macroscopic images of treated colons are shown in Figure 3 , and the entire data set for the 23 strains is tabulated in Figure 4 .
When scoring for hyperplastic lesions, we segregated AcB/BcA strains into two groups according to the strains genetic background, with all BcA strains showing numbers similar to the B6 parent (3ono6), and all AcB strains similar to the A/J parent (7ono11) (Figure 4a ), with no discordant strains. This suggests that the genetic basis of the differential induction of hyperplastic lesions in A/J and B6 mice is probably complex, with multiple genes involved and with no single congenic fragment transferred from the donor strain capable of influencing the phenotype of any of the AcB or BcA strains tested. As expected from their genetic background (87.5% from susceptible A/J), most AcB strains tested (five of six) developed tumors in numbers (12ono30) that were similar to parental A/J controls (Figures 4b and c) , with the exception of AcB52 that had very few tumors (closer to B6 controls). Conversely, BcA strains (87.5% from resistant B6) developed very few tumors, with the exception of BcA71, BcA72 and BcA87 that developed tumors in numbers (22ono35) similar to those detected in parental A/J controls (Figures 3 and 4c) . The resistant phenotype observed in AcB52 implies the inheritance of B6 genomic segment(s) that suppresses the tumorigenesis otherwise observed on the A/J background. On the other hand, a reciprocal set of RCS, BcA71, BcA72 and BcA87 showed susceptibility discordant with their parental B6 control due to an A/J-derived segment, suggesting the segregation of a major cancer susceptibility gene in those strains. In addition, strains BcA78, Colon cancer susceptibility locus Ccs3 C Meunier et al Genetic mapping of a major colon tumor susceptibility locus in AcB/BcA strains We undertook to map the major locus controlling tumor multiplicity in the AcB/BcA strains set. For linkage studies, we stratified AcB/BcA strains into two categories based on tumor numbers ( Figure 5 ), being either low or intermediate (o10 tumors) or high (>15 tumors). We left out of this stratification AcB58 that behaved as a true intermediate (nB9-11). This grouping produces a simple bimodal strain distribution pattern (SDP) that, when compared to SDPs of genetic markers tested in these mice, can localize the major gene effect controlling tumor numbers. Using this approach, we identified a perfect match between resistance and susceptibility to AOM-induced tumors and the haplotype combination on the distal portion of chromosome 3, with the A/J haplotype associated with susceptibility and the B6 haplotype associated with resistance ( Figure 5 ). Importantly, the three discordant BcA strains that show high tumor multiplicity, namely Bc71, BcA72 and BcA87, all show A/J haplotypes in this region, whereas the only discordant AcB strain displaying low tumor multiplicity (AcB52) harbors a B6 haplotype in this region ( Figure 5 , see labeled strains (*)). These results show that tumor multiplicity is controlled by a single locus in AcB/BcA strains, which has been given the temporary designation Ccs3, for colon cancer susceptibility locus 3. Transcript-profiling studies As a first step in the identification of possible positional candidates for Ccs3, we carried out transcript profiling with microarrays to detect which of the genes in the interval are expressed in the colon (Figure 6 ). Of the 94 annotated genes in the interval, 48 showed detectable mRNA expression levels in colon, for at least one of the probe sets on the array (Affymetrix, Santa Clara, CA, USA; mouse genome 430, version 2.0). Of these, 25 were expressed at robust levels and represent strong positional candidates. Supplementary Table 1 presents the list of these genes, grouped in five functional categories (transport, cell cycle/apoptosis, cell signaling, The maximum genetic interval for Ccs3 is identified. The phenotype of each strain with respect to tumor multiplicity is indicated at the bottom using the color code described in Figure 4 . AcB/BcA RCS for which the phenotypic outcome is discordant compared to the genetic background have been identified (*). The recombinant inbred strain BXA12 was also phenotyped and found to be 'resistant'; This strain shows an informative recombination event on the distal portion of chromosome 3, and was genotyped only for a subset of informative markers, which are shown.
Colon cancer susceptibility locus Ccs3 C Meunier et al metabolism and structural) and including a summary annotation of the known function of the encoded proteins. Several of these proteins can be identified as strong positional candidates for Ccs3, based on their known function. These include two proteins, Bcl10 and NFkB1, which have been associated directly with tumor initiation and/or progression, three proteins involved in guanylate nucleoside metabolism (Gbp2, Gbp3 and Rap1gds1) and one cytokine regulating activation of the monocyte/macrophage lineage (Scye1). We have also compared the level of expression of all genes in the interval in normal colon from susceptible A/J vs resistant B6 mice (Figure 7a ). Using a statistical cutoff of two-fold difference in expression (see Materials and methods), we identified three differentially The level of expression of the corresponding mRNAs in normal B6 intestine, as determined by transcript profiling with microarrays, is shown as histograms (averages and standard deviation from three independent arrays from three individual mice; total three measurements). Histograms represent the signal intensity detected per probe set (log 2 transformed). The dashed line across the histograms identifies genes that are strongly expressed in intestine, and that are considered positional candidates for Ccs3.
Colon cancer susceptibility locus Ccs3 C Meunier et al expressed genes, namely Slc39a8 (solute carrier family 39 member 8; metal ion transporter) and Ddah1 (dimethylarginine dimethylaminohydrolase 1; enzyme) that show reduced expression in A/J whereas Gbp1 shows dramatic increased expression (>8-fold) in A/J compared to B6 normal colon (Figure 7a) . A comparison of expression levels of all genes in the interval in colon tumors vs normal intestinal tissue (both from A/J) was also carried out ( Figure 7b ). This analysis identified seven genes (9130221D24Rik, similar to guanyl nucleotide exchange factors; Slc39a8, metal ion transporter; Adh1, alcohol dehydrogenase; Gbp1/Gbp2, guadenylate binding Expression difference is represented as log 2 -transformed fold change between the mean expression scores of the two strains (n ¼ 2 for each strain). In each comparative data set, genes containing probe sets showing differential expression suggesting alternative splicing (27 genes total) were identified by a & beside the gene symbol.
Colon cancer susceptibility locus Ccs3 C Meunier et al proteins; Clca3, calcium activated chloride channel; Mcoln2, cation channel), expression of which is downregulated in tumors, and five genes (Dkk2, negative regulator of Wnt signaling; Dapp1, adaptor for phosphotyrosine and phosphoinositide; Tspan5, integral membrane protein; Hs2st1, heparan sulfate 2-o-sulfotransferase-1 and Cyr61, cysteine-rich extracellular adhesion protein), expression of which is increased in tumors compared to normal tissue (Figure 7b ).
Finally, to look for the presence of alternatively spliced exons in the interval (quantitative differences in expression of normal mRNA variants from the same gene; genetic lesions abrogating normal splicing), we used exon arrays to measure expression of individual exons from all the genes. Two large data sets were compared: normal A/J colon vs normal B6 colon, and A/J colon tumors vs normal A/J colon. These data are presented in Figure 8 and include statistical evaluation Figure 8 Overview of probe set level (exon) expression in Ccs3 interval. Graphical representation of probe set expression levels for all core probe sets in the Ccs3 interval. (a) The DABG (detected above background) is a P-value indicating whether a probe set is expressed at a significant level above background. A P-value p0.05 (very short red bar) suggests the probe set is expressed, whereas P-values >0.05 (tall red bars) indicate the probe set is not expressed. Table 2 . To identify potential alternatively spliced transcripts in both comparative data sets, we selected individual probe sets showing differential expression above three standard deviations (s.d.) from the mean fold change for all probe sets with each gene, as well as a minimum log 2 ratio value of 1 (equivalent to two-fold change in expression). Genes in which >75% of probe sets showed differential expression with these criteria were not included, as they most likely represent a whole-gene expression change rather than an alternative splicing event. Overall, 27 unique genes (n ¼ 4 in B6 vs A/J, n ¼ 24 in tumor vs A/J) within the interval, including Rap1gds1, Gbp3, Dapp1 and Dkk2 (Figure 7 ), contain probe sets showing differential expression suggesting alternative splicing. The identification of genes in the Ccs3 interval that are (1) expressed in normal colon, and/or (2) differentially expressed in normal A/J vs B6 colon, and/or (3) differentially expressed in normal colon vs colon tumors and/or (4) which show evidence of alternate splicing in any of these combinations, now provides guidance for prioritization of positional candidates for further study.
Discussion
Chemical carcinogenesis in mouse models provides a powerful tool to study initiation and progression of CRC. Both DMH and its active metabolite AOM have been used to induce colon tumors (Dragani, 2003) . Although DMH treatment by i.p. injections induces tumors at a number of anatomical sites, AOM is more specific and causes lesions only in the colon. Our treatment protocol induced two types of lesions, namely hyperplastic lesions that were detected as early as 10 weeks after initiation of treatment, and tumors that were found in permissive animals starting around 14 weeks after initiation of treatment. These tumors consist in adenomas and in situ carcinomas, and a proportion of AOM-induced colon tumors have been shown to carry loss-of-function mutations in Apc and K-ras (Suzui et al., 2002; Takahashi and Wakabayashi, 2004 ; data not shown), highlighting the relevance of this model in the study of human tumors. Inbred strains of mice differ drastically in susceptibility to DMH or AOM chemical carcinogenesis (Evans et al., 1977; Deschner et al., 1988; Papanikolaou et al., 1998; Nambiar et al., 2003) . In this study, we carried out a systematic analysis of the genetic control of differential response to AOM chemical carcinogenesis in A/J and C57BL/6J mice. We observed that AOM induced hyperplastic lesions in both mouse strains, but these were more numerous in A/J. However, AOM induced tumors almost exclusively in A/J mice with very few detected in B6 (Figures 2 and 3) .
We have used AcB/BcA RCS to analyse the genetic basis of the differential response to AOM in A/J and B6. By virtue of the breeding scheme used in their derivation, AcB/BcA strains contain on average 12.5% genomic DNA from one parent (B6 in AcBs and A/J in BcAs) that has been transferred to the other parental genetic background (A for AcBs and B6 for BcAs). This 12.5% 'donor DNA' is present on specific sets of small congenic segments that are unique for every strain, and the position of which has been delineated by genotyping (Fortin et al., 2001) . RCS strains are extremely useful to study simple and complex traits. Indeed, if a phenotype distinguishing A/J and B6 is controlled by a single gene, then its location will be easily determined by examining the haplotype of AcB and BcA strains showing a discordant phenotype about parental genetic background, (for example, a BcA strain that behaves like A/J, and an AcB strain that behaves like B6), and identifying the syntenic segments commonly inherited in these strains (Fortin et al., 2001; Tuite et al., 2005) . This is clearly the case in this study. In the case of monogenic traits, the RCS strain set is more powerful than standard backcross or F2 mapping panels, to quickly and reproducibly delineate the chromosomal boundaries of the major locus, as multiple animals from the key strains (bearing informative recombinant haplotypes) can be sampled at will. In the case of multigenic control, single gene effects contributing to a polygenic trait may have segregated from one another and become fixed in individual strains, allowing one to study their contribution and mechanism of action in isolation (Min-Oo et al., 2007) . In addition, simple examination of the SDP of the RCS set for multiple subphenotypes contributing to a trait distinguishing A/J and B6 parental strain may not only reveal the functional architecture of these subtraits, but also help determine which ones are determined by the same or different genetic control. Finally, unique reassortment of parental haplotypes and emergence of novel mutations during the breeding of the RCS (Van Wezel et al., 1996; Min-Oo et al., 2003; Fortin et al., 2007) may provide additional phenotypic diversity in the study of a complex trait.
In this study, we observed that all AcB strains tested had similar number of hyperplastic lesions and that these numbers were approximately twice as high as the number of such lesions found in BcA strains, with no obvious discordant strains in either group. The situation was different for the number of AOM-induced tumors. Indeed, the majority of BcA were B6-like (low tumor multiplicity) with the notable exception of BcA71, BcA72 and BcA87 that were discordant (high tumor multiplicity). Similarly, the tested AcBs were A/J-like with the notable exception of AcB52 that was discordant and B6-like. A number of conclusions can be reached from this data set. First, the different SDPs of AcB/BcA mice for the number of AOM-induced hyperplastic lesions vs number of colorectal tumors indicate that the two traits are under different genetic controls in A/J and B6. The different genetic control of AOM-induced preneoplastic lesions and colon adenomas noted herein in the AcB/BcA RCS has also been observed in parallel studies of DMH-treated CcS/Dem RCS strains . Second, the genetic control of AOMinduced hyperplastic lesions is likely to be complex and multigenic, with the transfer of 12.5% of the genome from either A/J or B6 in BcA and AcB strains, respectively, having no influence on this trait. Third, the genetic control of AOM-induced tumors behaves as a simple trait, and haplotype analysis shows a major gene effect on the distal portion of chromosome 3 that we designate Ccs3. Fourth, the presence of multiple tumors in BcA71, BcA72 and BcA87 that have low numbers of hyperplastic lesions, and conversely, low tumor multiplicity in AcB52 despite high numbers of hyperplastic lesions, suggests that one is not a prerequisite for the other. Finally, the intermediate number of tumors detected in AcB58 suggests the presence of additional genetic modifiers in that strain.
A locus (Ccs2) influencing DMH-induced colon tumor multiplicity in (C57BL/6J Â CBA/J) backcross and F2 mice has been regionally assigned to mouse chromosome 3 (D3Mit147, D3Mit19; cumulative LOD4.6) (Angel et al., 2000) . It is possible that the chromosome 3 effect (Ccs3) detected here in AOMtreated AcB/BcA strains is identical to Ccs2. However, several lines of evidence suggest that they may be different, and this is why we have retained the temporary designation Ccs3. Ccs2 was detected using a different treatment (DMH vs AOM), and a different mouse strain combination (B6 and CBA/J). In addition and as opposed to Ccs3, the genetic control did not appear to segregate as a monogenic trait in (B6 Â CBA)F2 and backcross mice, and the linkage peak for Ccs2 maps distally to Ccs3 on chromosome 3 (Angel et al., 2000) . Finally, haplotype mapping with multiple single nucleotide polymorphisms from this region failed to identify a conserved haplotype on that segment of chromosome 3 between A/J, CBA/J and C57BL/6J, a situation that might be expected for a conserved interstrain genetic control such as that detected for the Char9 locus in malaria susceptibility (Min-Oo et al., 2007) and the Nramp1 locus and susceptibility to intracellular infections (Malo et al., 1994) . Further experimentation will be required to determine if Ccs2-and Ccs3-inherited phenotype are caused by the same gene.
There are several obvious positional candidates within the maximum 14 Mb Ccs3 interval that contains at least 94 annotated genes, with 25 of them showing robust mRNA expression in normal colon. Bcl10 (145.6 Mb) is a signaling molecule and caspase regulator that has proapoptotic activity important for the development and activation of B and T lymphocytes (Thome, 2004) . Null Bcl10 mouse mutants show severe immunodeficiency (Xue et al., 2003) . Bcl10 is disrupted in the t(1;14)(p22;q32) translocation found in humans with MALT B-cell lymphoma, and is also mutated in a number of other lymphoid and solid tumors, including colonic carcinoma cell lines Lovo and LS513 (Willis et al., 1999) . Interestingly, it was recently reported that the Bcl10/Malt1 complex is involved in NF-kB activation for cytokine production (Gross et al., 2008) . NF-kB (p105; 135.6 Mb) is a transcription factor that plays an important role in innate immunity and inflammatory response by regulating production of key cytokines and chemokines. NF-kB has anti-apoptotic activities and overexpression of NF-kB has been associated with bowel inflammatory conditions (ulcerative colitis, Crohn's disease) and with colorectal tumors (Greten et al., 2004; Pacifico and Leonardi, 2006) . More specifically, mutations in the NF-kB-activating kinase Ikkb cause a reduction in total tumor burden in mice treated with a combination of AOM (i.p., single dose) and the irritant dextran sulfate (p.o., 3 weekly doses) (Karin, 2008) . These results suggest that NF-kB is a strong candidate for Ccs3. The Rap1gds (138.7 Mb) gene (Rap1 GTP/GDP dissociation stimulator) is another interesting positional candidate. Rap1 has a role in cell differentiation, cell proliferation and apoptosis; Rap1 interacts with two effectors of the Mek/Erk mitogenactivated protein kinase pathway, namely Raf-1 and BRaf (Stork, 2003; Stork and Dillon, 2005) . As an inhibitor of the Raf1 pathway, Rap-GTPase is an antagonist of Ras-GTPase, a group of proteins known to be critical in the progression of colorectal tumors. Finally, there are two additional guanylate binding proteins with GTPase activity that map within the Ccs3 interval, Gbp2 (142.2 Mb) and Gbp3 (142.3 Mb).
The retroviral tagged cancer gene database (RTCGD; Akagi et al., 2004;  http://rtcgd.ncifcrf.gov) compiles all known retroviral and transposon integration sites and corresponding genes that are associated with the appearance of hematological tumors (T-cell lymphomas, myeloid leukemias) in mouse experimental models (from 17 different laboratories). A search of this database has revealed four common insertion sites in the Ccs3 region that alter expression of four corresponding genes, namely NF-kb1, Rg9mtd2, Rap1gds1 and Bcl10. Together with their known biological function (discussed above), these observations further strengthen the candidacy of these genes as being responsible for the Ccs3 effect.
Positional cloning with further reduction of the genetic interval and systematic sequencing of all genes in the interval is currently being undertaken, and will ultimately be required to identify the causative genetic lesion at Ccs3. In addition to the 4-6 obvious candidates reviewed above, additional prioritization for characterization and validation will take into account the transcript and exon profiling data presented in Figures 7 and 8. Priority will be given to genes in the Ccs3 interval that are (a) differentially expressed in normal A/J vs B6 colon, and/or (b) differentially expressed in normal colon vs colon tumors, and/or (c) which show evidence of interstrain difference in alternate splicing in normal colon or in colon tumors. Finally, validation of possible positional candidates will be obtained by functional complementation in vivo, using transgenic mice carrying bacterial artificial chromosome (BAC) clones from the region. In these experiments, BAC clones overlapping the minimal genetic/physical interval for Ccs3 will be transferred to the germ line of A/J (either directly or after backcrossing), followed by testing for correction of the tumor susceptibility phenotype in A/J transgenic animals expressing the B6 parental copy of the positional candidates.
The Ccs3 interval on mouse chromosome 3 shares synteny relationship with interspersed portions of human 4q21-25 on the proximal side and human 1p22-31 on the distal side. Interestingly, human 4q and human 1q regions have been associated with inflammatory bowel disease and CRCs. Human chromosome 4q gave positive association in a genome-wide screen of 297 individuals with Crohn's disease and ulcerative colitis (in a familial setting) (Cho et al., 1998) . Genome instability or loss of heterozygosity at human 4q or both have been detected in a number of solid tumors, including esophageal adenocarcinoma (Nancarrow et al., 2008) , hepatocellular carcinoma (Herath et al., 2006) and CRC (Kurashina et al., 2008) .Conversely, recent genome-wide association studies in several thousand patients with Crohn's disease have identified the 1p31 region as a very strong genetic contributor (Cho et al., 1998; Barrett et al., 2008) . Finally, a large body of published data has associated human 1p with colon cancer. For example, allelic imbalance at 1p has been noticed in up to 10% of small adenomas (Shih et al., 2001) . Other studies have detected 1p deletions in colorectal polyps (Lothe et al., 1995) , and 1p alterations (LOH, allelic imbalance, deletions) have been detected in up to 30-80% of colorectal tumors in humans (Couturier-Turpin et al., 2001; Cianciulli et al., 2004) . It is tempting to speculate that the same gene or set of genes may contribute to inflammatory bowel diseases and colorectal tumors in humans and may underlie the Ccs3 effect mapped in our study. Therefore, identifying the gene responsible for the Ccs3 phenotype may help further understand pathogenesis of inflammation and/or CRC in humans.
Materials and methods
Mice
Inbred A/J and C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). The AcB/BcA set of RCS were derived from a double backcross (N3) between A/J and C57BL/6J parents at McGill University. The breeding, genetic characteristics and genotype of these animals for 625 markers have been previously described (Fortin et al., 2001) . The 35 AcB/BcA strains were maintained at the Animal Care Facility of McGill University according to the guidelines of the Canadian Council on Animal Care. They were fed regular chow and water ad libitum.
Carcinogen treatment and colon tumor preparations Azoxymethane was purchased as a single lot from Sigma (St Louis, MO, USA), and stored as 25 mg aliquots at À20 1C. For each injection, a fresh aliquot was thawed and appropriately diluted. Age-matched male and female mice (12-week old) were injected intraperitoneally with AOM (Sigma) dissolved in saline at a dose of 10 mg/kg of body weight, once per week, for 8 weeks. The animals were weighed and examined twice per week for appearance of clinical symptoms. Animals showing discomfort were immediately killed. End points were defined as 19-20 weeks after the first injection. At least 10 mice of each genotype were tested per experiment. After killing the mice, the entire colon was removed, flushed with cold PBS, sectioned longitudinally and fixed flat on 10% paraformaldehyde-soaked Whatman filter paper. The same person scored either tumors (protruding masses with thick/opaque interior) or hyperplastic lesions (flat structures showing hollow interior). The approximate volume of each tumor was calculated by the formula ((diameter/2) 3 Â p Â 2/3) and tabulated for each mouse and for each mouse strain.
Preparation of tissues, histological analyses
The mice were killed and intestines were immediately removed, washed in PBS and fixed in 10% phosphate-buffered formalin and processed for immunohistochemistry. Fixed tissues were dehydrated in ethanol and embedded with paraffin. Tissue sections, 6 mm in thickness, were deparaffinized according to standard protocols, mounted onto slides, stained with eosin and counterstained with hematoxylin, following standard histological procedures. Grading of tumors was performed by a pathologist (SJ). Images were acquired using a Zeiss Axiovert instrument (Zeiss Canada, Toronto, ON, Canada), and processed using Adobe Photoshop (www.adobe.com).
Transcript profiling with microarrays
Colons were dissected, rinsed with PBS and snap-frozen in liquid nitrogen (three mice per experimental group). Tissue was disrupted using a Polytron homogenizer (Brinkmann Instruments, Mississawga, ON, Canada), and total RNA was isolated using TRIzol reagent following the manufacturer's instructions (Invitrogen, Burlington, Ontario, Canada). The RNA quality was assessed using RNA 6000 NanoChips with the Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). Biotin-labeled target for the microarray experiment were prepared using 1 mg total RNA. The RNA was subjected to an rRNA removal procedure with the RiboMinus Human/ Mouse Transcriptome Isolation Kit (Invitrogen) and cDNA was synthesized using the GeneChip WT (Whole Transcript) Sense Target Labeling and Control Reagents kit as described by the manufacturer (Affymetrix). The sense cDNA was then fragmented by UDG (uracil DNA glycosylase) and APE 1 (apurinic/apyrimidinic endonuclease 1) and biotin-labeled with terminal deoxynucleotidyl transferase using the GeneChip WT Terminal labeling kit (Affymetrix). Selected RNAs were used for transcriptional profiling with Affymetrix oligonucleotides chips (Mouse Genome 430 2.0 array), according to the manufacturer's recommendations. Raw data generated by GeneChip Operating Software were normalized using GeneSifter microarray data analysis system (VizX Labs, Seattle, WA, USA; www.genesifter.net), using RMA (Robust Multi-Array) normalization. This analysis revealed that 78 of the 94 annotated genes in the Ccs3 interval are expressed in colon.
For exon arrays, hybridization was performed using 5 mg of biotinylated target, which was incubated with the GeneChip Mouse Exon 1.0 ST array (Affymetrix) at 45 1C for 16-20 h. Following hybridization, nonspecifically bound material was removed by washing, and detection of specifically bound target was performed using the GeneChip Hybridization, Wash and Stain kit, and the GeneChip Fluidics Station 450 (Affymetrix). The arrays were scanned using the GeneChip Scanner 3000 7G (Affymetrix) and raw data were extracted from the scanned images and analysed with the Affymetrix Power Tools software package (Affymetrix). The Affymetrix Power Tools software package (Affymetrix) was used to quantile normalize the probe fluorescence intensities and to summarize the probe set (representing exon expression) and meta-probe set (representing gene expression) intensities using a probe logarithmic intensity error model (see http://www.affymetrix.com/support/ technical/technotes/plier_technote.pdf). A variance stabilization constant of 16 was added to all PLIER scores before log transformation. Only the high-confidence set of core probe sets and core meta-probe sets were used in the analysis.
Linkage analysis in AcB/BcA recombinant congenic strains The published genetic map of the AcB/BcA RCS set was used to identify congenic segments associated with tumor susceptibility following AOM treatment (Fortin et al., 2001) . Quantitative trait loci were first determined by computing single marker regressions with MapManager QTX software, using average number of tumors as a phenotypic marker (Manly et al., 2001) . A self-RI model, which implicitly considers each background (A/J or B6) as an independent RI set, was used for the analysis. The markers with highest linkage values were subsequently positioned on the July 2007 mouse (Mus musculus) genome data obtained from the Build 37 assembly by NCBI to attribute physical genomic positions. Fine-mapping of the locus interval was appraised by visual tracking of haplotypes in contributing and non-contributing strains. In a second analysis, analysis of variance was used to first compare the number of tumors displayed in each RCS strain to the one of its corresponding parental strains. Using this simple test, we qualitatively scored each strain as A/J-like or B6-like (binary phenotype). The obtained SDP was then compared to the genetic map of the RCS panel using a simple computer program scoring percentage of similarity between the loci and the phenotypes.
